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Abstract
Background: Allelic counterparts of biallelically expressed genes display an epigenetic symmetry
normally manifested by synchronous replication, different from genes subjected to monoallelic
expression, which normally are characterized by an asynchronous mode of replication (well
exemplified by the SNRPN imprinted locus). Malignancy was documented to be associated with
gross modifications in the inherent replication-timing coordination between allelic counterparts of
imprinted genes as well as of biallelically expressed loci. The cancer-related allelic replication timing
aberrations are non-disease specific and appear in peripheral blood cells of cancer patients,
including those with solid tumors. As such they offer potential blood markers for non-invasive
cancer test. The present study was aimed to gain some insight into the mechanism leading to the
replication timing alterations of genes in blood lymphocytes of cancer patients.
Methods: Peripheral blood samples derived from patients with prostate cancer were chosen to
represent the cancerous status, and samples taken from patients with no cancer but with benign
prostate hyperplasia were used to portray the normal status. Fluorescence In Situ Hybridization
(FISH) replication assay, applied to phytohemagglutinin (PHA)-stimulated blood lymphocytes, was
used to evaluate the temporal order (either synchronous or asynchronous) of genes in the patients'
cells.
Results: We demonstrated that: (i) the aberrant epigenetic profile, as delineated by the cancer
status, is a reversible modification, evidenced by our ability to restore the normal patterns of
replication in three unrelated loci (CEN15,  SNRPN  and  RB1) by introducing an archetypical
demethylating agent, 5-azacytidine; (ii) following the rehabilitating effect of demethylation, an
imprinted gene (SNRPN) retains its original parental imprint; and (iii) the choice of an allele between
early or late replication in the aberrant asynchronous replication, delineated by the cancer status,
is not random but is independent of the parental origin.
Conclusion: The non-disease specific aberrant epigenetic profile displayed in peripheral blood
cells of patients with a solid tumour (unlike genetic aberrations) can be reversed, by an epigenetic
drug applied in vitro, to the normal. It appears that the cancerous status differentiates between two
allelic counterparts in a non-random manner, but independent of the parental origin
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Background
The fundamentals of Mendelian genetics lead to the
assumption that genes of the parental genomes in mam-
mals keep a functional symmetry: the two alleles function
or shut off concomitantly in what is called biallelic expres-
sion. However, a subset of the genes is subjected to allele-
specific expression (monoallelic expression), in which
only one allele retains expression capability while its
counterpart is silent [1,2]. Monoallelically expressed
genes include imprinted genes [3-5], X-linked genes sub-
jected in female cells to X-chromosome inactivation [6,7],
and genes displaying allelic exclusion [8,9].
The functional asymmetry of alleles of an imprinted gene
depends upon the parental origin of the allele – whether
maternal or paternal. It is established during germ-cell
development into sperm or eggs, and after fertilization
each allele maintains its parental imprint, which segre-
gates almost unchanged in the developing organism [5].
In contrast to the process of imprinting, in the processes
of X-inactivation and allelic exclusion, the choice of an
allele to be activated or silenced is not associated with
parental origin. In the X-inactivation and allelic exclusion
processes the functional capability or incapability is deter-
mined in a kind of stochastic selection by an as yet
unknown selection in each individual cell: one allele stays
potentially active and its partner becomes incapable of
expressing itself [reviewed in [10]]. This pattern is nor-
mally maintained in a clonally-dependent manner
throughout cell proliferation, enabling each tissue to carry
a potentially active paternal allele in some cells and a
potentially active maternal allele in other cells, the fre-
quencies of the two cell types usually deviate from ran-
dom; in some cases most of the cells (of a given tissue)
carry an active maternal allele while in others most of the
cells (of the very same tissue) display an active paternal
allele, giving rise to a non-random pattern but independ-
ent of the parental origin [6,7,11-14].
Whatever the mechanisms involved in the maintenance
and selection of an allele for allele-specific expression, the
functional asymmetry of monoallelically expressed genes
results from the two alleles maintaining different epige-
netic profiles, in which asynchronous DNA replication,
similar to differential DNA methylation, plays a decisive
role [reviewed in [12]].
The method of choice for evaluating the temporal order of
allelic replication is the fluorescence in situ hybridization
(FISH) replication assay [11,15-18]. This assay was first
developed to confirm and reinstate previous observations
that two homologous counterparts usually replicate con-
comitantly, and to demonstrate unequivocally that the
two alleles of a biallelically expressed gene replicate syn-
chronously, early in cells of expression and late in unex-
pressed cells [19]. Using this assay an asynchronous
pattern of allelic replication – early replication of the
potentially active allele and late replication of the silent
one – was shown, not necessarily in the cells of expres-
sion, for all known types of monoallelically expressed
genes: (i) imprinted genes [20-26], (ii) genes subjected to
X-chromosome inactivation [27-29], and (iii) genes
undergoing allelic exclusion [11,13,15,30,31].
We reported previously that imprinted genes lose their
characteristic epigenetic-asymmetry, as reflected in loss of
asynchronous replication, in peripheral blood lym-
phocytes of patients with a solid tumor such as renal cell
carcinoma [25] or prostate cancer [26]. This is in accord
with studies documenting loss of the allele-differential
methylation characterizing imprinted genes, a phenome-
non often referred to as "loss of imprinting" (LOI) in
peripheral blood lymphocytes of patients with a solid
tumor such as colon cancer [32,33]. Furthermore, classical
biallelically expressed genes, exemplified by RB1, TP53,
AML1 and C-MYC, which normally display a synchronous
mode of allelic replication, yet in peripheral blood lym-
phocytes of patients with a solid tumor, such as renal cell
carcinoma [25] or prostate cancer [26], exhibit an asyn-
chronous pattern of replication similar to that characteriz-
ing normally monoallelically expressed genes. Even
satellite chromosome-specific sequences (pericentromeric
non-coding DNA arrays), which normally display syn-
chrony in replication of homologous counterparts, simi-
lar to biallelically expressed genes, change their inherent
replication mode and replicate asynchronously in lym-
phocytes of patients with cancer, including ovarian [34],
hematological [35] and prostate cancers [26]. Consider-
ing that biallelically expressed genes in cells of cancer
patients, similar to imprinted genes, are subjected to the
global epigenetic disequilibrium associated with tumori-
genesis [36], these replication alterations are inevitable.
The feasibility to observe a cancer-linked marker in
peripheral blood cells of cancer patients would be of
immense value in cancer diagnosis and therapy [37], espe-
cially if it is based on DNA itself rather than on a DNA
product.
The present study was aimed to gain some insight into the
process leading to the replication timing alterations of
genes in the blood lymphocytes of cancer patients. Specif-
ically, we checked: (i) if the cancer-related loss of asyn-
chronous replication of an imprinted gene, and "gain" of
asynchrony of loci that normally replicate synchronously
are linked to aberrant methylation; and (ii) whether the
choice of an allele for early or late replication in cancer-
related asynchronous replication is random, dependent of
the parental origin or non-random but independent of
the parental origin.BMC Cancer 2008, 8:390 http://www.biomedcentral.com/1471-2407/8/390
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Methods
Study subjects
Forty-four male urology patients were included in the
study, 22 with prostate cancer (CAP), and 22 with no can-
cer but with benign prostate hyperplasia (BPH). Diag-
noses were based on histological examination of tissues
removed from the prostate gland by surgery or biopsy. The
study also included two healthy family members, the wife
(designated K1) and son (designated K2) of one of the
non-cancer (BPH) patients (designated K). The 44
patients and the two family members of patient K had
normal karyotypes, based on G-banded metaphase
spreads.
Lymphocyte cultures
Each subject donated 5 ml of peripheral blood prior to an
invasive diagnostic procedure (surgery or biopsy), or
medical treatment (hormonal, radiation, or chemother-
apy). Cell cultures of PHA-stimulated lymphocytes were
set up according to the standard protocol used for routine
karyotype assays described previously [26]. Briefly, blood
samples were cultured in F10 medium containing 20%
fetal calf serum (FCS), 3% phytohemagglutinin (PHA),
0.2% heparin, and 1% antibiotics. Six of the 22 samples
derived from the cancer (CAP) patients (designated C1–
C6) and six of the 22 samples obtained from the non-can-
cer (BPH) patients (designated B1–B6) were also cultured
in the presence of 10-7  M 5-azacytidine (AZA; Sigma
Chemicals, St. Louis, MO. USA), added to the other ingre-
dients of the medium. Cultures were incubated at 37°C
for 72 h, colchicine (final concentration of 0.1 μg/ml) was
added for 1 h, and hypotonic treatment (0.075 M KCl at
37°C for 15 min) and four washes were carried out, each
with a fresh cold fixation solution (3:1 methanol: acetic
acid solution). The cell suspensions in the fixative solu-
tion were stored at -20°C until analysis by FISH.
DNA probes
Three directly labeled commercial probes obtained from
Vysis Inc. (Downers Grove, IL, USA) were used: (i) the
SNRPN  probe (32–190004), which identifies the
imprinted SNRPN gene, located on the long arm of chro-
mosome 15 (15q11-q13, within the Prader-Willi/Angel-
man syndrome imprinted region) adjacent to the
centromere; (ii) the RB1 Probe (32–190001), which iden-
tifies the retinoblastoma tumor suppressor gene, a classi-
cal biallelically expressed gene [38]; and (iii) the CEN15
probe (32–130015), which identifies the pericentromeric
region of chromosome 15 (CEN15). CEN15 was consid-
ered appropriate because it faithfully mimics the replica-
tion mode of a biallelically expressed locus, it has a size
polymorphism that enables identification of each specific
allelic counterpart in informative cells, and it is located in
the vicinity of the SNRPN, whose replication status tells
the parental origin of the chromosome [20,23], enabling
easy determination of the parental origin of each CEN15
morph (for details see Fig. 1).
Probe application
Applying one-color FISH, each of the 44 samples derived
from the urology patients was hybridized individually
with the SNRPN probe and the CEN15 probe. In addition,
each of six samples from the BPH group of patients (cases
B1–B6) and each of six samples from the CAP group
(cases C1–C6), was hybridized with the RB1 probe too.
Of the 44 samples, 11 were polymorphic for a large
CEN15  marker: five from the BPH group (including
patient K) and six from the CAP group. These 11 samples
and the sample from the healthy son (K2) of patient K
were all hybridized concomitantly with two probes,
SNRPN and CEN15 (two-color FISH). The sample of the
wife of patient K (K1) was hybridized with the CEN15
probe only and displayed two normal, equal-sized CEN15
signals, verifying that the large CEN15 marker of K2 (Fig.
1) was of paternal origin.
In-situ hybridization
We followed a protocol previously described [26]. Cells
were dropped onto two-well slides (Insitus Biotechnolo-
Cells of a healthy (cancer free) individual (case K2) hetero- zygous for the large CEN15 marker (derived from the pater- nal parent) after two-color FISH with SNRPN (red signals)  and CEN15 (green signals) Figure 1
Cells of a healthy (cancer free) individual (case K2) 
heterozygous for the large CEN15 marker (derived 
from the paternal parent) after two-color FISH with 
SNRPN (red signals) and CEN15 (green signals). Left, 
two interphase cells representing SD cells for SNRPN and SS 
cells for CEN15. Right, cell at metaphase with chromosome-
15 homologues identified by the CEN15 and SNRPN signals. 
Note the difference in signal size between the two CEN15 
counterparts in each cell, and the association of the repli-
cated SNRPN locus (doublet; D-signal) in both interphase 
cells with the large CEN15.BMC Cancer 2008, 8:390 http://www.biomedcentral.com/1471-2407/8/390
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gies, Albuquerque, NM, USA) with no pretreatment. Five
μl of the probe solution, diluted in D003 (SNRPN and
RB1) or D001 (CEN15) Ingen's DenHyb hybridization
solution (Insitus Biotechnologies), were placed on the tar-
geted area of the sample slides, covered with a 12 mm
round silianized coverslip (Insitus Biotechnologies), and
sealed with rubber cement. The slides were placed in a
micro-heating system (Vysis Inc.), programmed first for 6
min denaturation at 76°C and then for 18 hours hybridi-
zation at 37°C.
Post-hybridization treatments
Following removal of the coverslips, post-hybridization
washes consisted of immersing the slides for 2 min in a
solution of 0.4 × SSC pH 7.0 with 0.3% NP40 at 72°C,
followed by 2 min in 2 × SSC with 0.1% NP40 at room
temperature in a shaking water bath. After brief drying,
the slides were covered with an antifade solution contain-
ing 4,6-diamidino-2-phenylindole (DAPI; 3 μg/ml; Vector
Laboratories, Inc., Burlingame, CA, USA), coated with
glass coverslips, and stored at -20°C until analyzed.
Cytogenetic evaluation
Slides were analyzed blindly on an Olympus BH2 fluores-
cent microscope equipped with a triple band-pass filter
(Chroma Technology, Brattleboro, VT, USA). The FISH
replication assay was used to estimate the replication sta-
tus of each allelic region as described previously [26].
Accordingly, the structure of the fluorescent signal of each
identified region was noted: either singlet (S), denoting a
non-replicated sequence, or doublet (D), disclosing a rep-
licated sequence. Thus, in a population of replicating
cells, the frequency of cells exhibiting an "S" signal for one
allele and a "D" signal for the other (SD cells), out of the
total population of cells with two fluorescent signals, rep-
resented the level of asynchrony in the replication timing
of the identified alleles. High SD-cell frequency indicated
an asynchronous mode of replication, and low frequency
a synchronous mode [16,17,20].
For estimation of the frequency of SD cells at least 100
cells with two clear signals were scored from each sample,
for each treatment, for each locus, following one-color
FISH with the relevant probe. To differentiate a specific
CEN15 or SNRPN allele from its allelic counterpart based
on the size-polymorphism of the CEN15 fluorescent sig-
nal, at least 200 SD cells for the locus in question were
scored from each informative sample; for CEN15 differen-
tiation one-color FISH (with the CEN15 probe) and for
SNRPN differentiation two-color FISH (with the CEN15
and the SNRPN probes) were applied.
Statistical method
The statistical significance of the differences between two
cell populations was determined using the two-tailed Stu-
dent's t-test (Microsoft Excel) and a P value < 0.01 was
considered statistical significant.
Ethical basis
Informed consent was obtained from each individual
examined, and the Ethics Committee of the Sheba Medi-
cal Center approved the study.
Results
Replication timing alterations of SNRPN and CEN15 in 
cells of cancer patients are readjusted in the presence of 5-
azacytidine (AZA, a methylation-blocking agent)
The frequency of SD cells (see 'Cytogenetic evaluation' in
Materials and Methods) for SNRPN was high in cells of
the cancer-free urology patients, as expected for an
imprinted region in normal samples. However, this very
same locus in the samples of the cancer patients revealed
low SD values, significantly lower (P < 10-11) than the
expected values (Fig. 2; Table 1). In addition, the CEN15
alleles, which normally replicate synchronously, as seen
here in the cells of the non-cancer patients (Fig. 2a), repli-
cated highly asynchronously in the cells of the cancer
patients, similar (P > 0.30) to the SNRPN in the cells of
cancer-free patients (Fig. 2; Table 1). Thus, the cells of the
cancer patients exhibited an abnormal mode of allelic rep-
lication: low SD values for SNRPN, which were signifi-
cantly lower (P < 10-11) than the SD values obtained in the
same samples for the CEN15 locus (Fig. 2b), and only
slightly higher (P < 0.02) than the low SD value shown for
CEN15 in the non-cancer samples (Fig. 2; Table 1). At the
same time, the cells of the cancer-free urology patients
exhibited the normal pattern of replication: high SD val-
ues for SNRPN and significantly lower (10-12) values for
CEN15 (Fig. 2a).
The abnormal SD values for SNRPN and CEN15 in the
cells of the cancer patients were shifted toward normal in
the presence of AZA, a methylation-blocking agent (Fig.
3b and 3d). In contrast, the samples of the non-cancer
patients were not affected by AZA (Fig. 3a and 3c), evi-
denced by the lack of difference, in the presence of AZA,
between the cancer cases and the non-cancer cases in the
SD values for SNRPN as well as for CEN15 (Fig. 3).
It is noteworthy that CEN15 mimics the replication tim-
ing of RB1: (i) low SD values in cells of cancer-free
patients, both with and without AZA; (ii) high SD values
in the cells of the cancer patients, similar to those
obtained for an imprinted region in normal cells; and (iii)
a decrease in the abnormal (high) SD values in the cells of
the cancer patients to normal low levels in the presence of
AZA (Fig. 3c–f).BMC Cancer 2008, 8:390 http://www.biomedcentral.com/1471-2407/8/390
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The loss of the asynchronous pattern of SNRPN 
replication in cells of cancer patients is not accompanied 
by randomization of the early and late replicating alleles
Following one-color FISH with the CEN15 probe, 11 of
the 44 samples studied were heterozygous for CEN15 size:
six derived from cancer (CAP) patients (designated Y, J, A,
C, B, and S), and five from non-cancer (BPH) patients
(designated G, V, R, Z, and K). Each displayed at both
interphase and metaphase one large and one small
CEN15 signal (illustrated in Fig. 1). The son of patient K
was a young healthy man (K2) who happened to be het-
erozygous for a large CEN15 marker (Fig. 1), similar to his
father (K); his mother (K1) was homozygous for two
small CEN15 markers (data not shown).
Using two-color FISH to identify the CEN15  and the
SNRPN in the same cell, we examined the population of
SD cells for SNRPN in the samples heterozygous for the
large CEN15 marker. The early replicating SNRPN allele
was not randomly distributed between the two chromo-
some-15s in either the informative (heterozygous) sam-
ples derived from non-cancer cases (Fig. 4a) or those
derived from the informative cancer cases (Fig. 4c). Specif-
ically, in the samples of the non-cancer BPH cases (G, R
and K), in the K2 sample, and in one sample of a cancer
(CAP) case (J), the early replicating SNRPN  allele was
located in more than 70% of SD cells on the chromosome
carrying a large CEN15 marker. On the other hand, in
samples V and Z derived from non-cancer patients, as well
as samples Y, A, and C derived from cancer patients, the
early replicating SNRPN allele was found in more than
75% of SD cells on the chromosome identified by a small
CEN15 marker (Fig. 4a and 4c). This clearly showed that
the relaxation in the asynchronous replication of SNRPN
(reduced SD-cell frequency) that characterizes samples of
cancer patients was not accompanied by randomization
of the early and late replicating alleles.
SD values for SNRPN and CEN15 in cells of two groups of urology patients Figure 2
SD values for SNRPN and CEN15 in cells of two groups of urology patients: (a) patients free of cancer (BPH); and (b) 
cancer patients (CAP). The values in each frame for each locus are presented in increasing order. P – the level of significance of 
the differences between the SNRPN and the CEN15 loci within a group of patients.
Table 1: Level of significance of the differences (P) in SD values 
for the designated loci between samples of patients free of 







P < 10-11 P < 0.02
CAP CEN15
(37.8 ± 5.1%)
P > 0.30 P < 10-12
In parentheses are the mean SD frequency (%) and the standard 
deviation value for the group of patients for the particular locus. Each 
group contained 22 cases (the compared values are presented in 
Figure 2).BMC Cancer 2008, 8:390 http://www.biomedcentral.com/1471-2407/8/390
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SD values for the SNRPN, CEN15 and RB1 loci, in the absence (❍) and in the presence (▲) of AZA Figure 3
SD values for the SNRPN, CEN15 and RB1 loci, in the absence (❍) and in the presence (▲) of AZA. (a), (c) and (e) 
values of patients free of cancer (BPH cases); (b), (d) and (f) values of urology cancer patients (CAP cases). P – the level of sig-
nificance of the differences between corresponding values obtained in the presence and absence of AZA.BMC Cancer 2008, 8:390 http://www.biomedcentral.com/1471-2407/8/390
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Characterization of the SD-cell populations for SNRPN and CEN15 in cell samples of individuals heterozygous for the CEN15  size, showing one large and one small CEN15 marker Figure 4
Characterization of the SD-cell populations for SNRPN and CEN15 in cell samples of individuals heterozygous 
for the CEN15 size, showing one large and one small CEN15 marker. Light bars show the portion (%) of the relevant 
SD-cell population in which the replicated region (D-signal) is associated with the large CEN15 marker, and dark bars show the 
SD-cell portion in which the D-signal is associated with the small CEN15 marker. (a) and (b) samples of cases free of cancer (K2 
was from a healthy young man, the son of K); (c) and (d) samples of cancer patients; the last bar in frame (c) is a sample of can-
cer patient C (case C5 in Fig. 3) grown in the presence of AZA; at least 200 SD cells were scored from each sample for each 
assay.BMC Cancer 2008, 8:390 http://www.biomedcentral.com/1471-2407/8/390
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Moreover, the rehabilitating effect of AZA, which restored
the normal high SNRPN SD values in cancer samples (Fig.
3b), reinstated the early replicating SNRPN allele on the
same chromosomal counterpart at which the early repli-
cating allele was located in the absence of the drug (appar-
ently the paternal chromosome). This was demonstrated
by cancer case C: in most of the SD cell population for
SNRPN the early replicating allele was on the chromo-
some identified by a small CEN15 marker both before and
after AZA application (see the two last bars in Fig. 4c).
Worthy of notice that K2 is of particular interest here
because the parental origin (paternal) of the large CEN15
marker was known, and the early replicating SNRPN allele
was indeed associated with the paternal chromosome (see
last two bars in Fig. 4a). Moreover, the results of the father
(K) and the son (K2) confirmed previous findings [20,23]
that, in informative CEN15 cases, the replication status of
the SNRPN locus enables identification of parental origin
of chromosome 15 with no need for family studies, which
are usually complicated, especially in elderly subjects.
The allelic choice for an asynchronous pattern of 
replication for CEN15 in cells of cancer patients is a non-
random event, but is not associated with a parent-of-
origin-dependent effect
Next, we undertook to determine whether the choice of an
allele in the cancer-related process of allele-specific repli-
cation is a random event. Using the informative (hetero-
zygous)  CEN15  samples, we analyzed the SD-cell
population for CEN15 and found that the early replicating
CEN15 allele in the cancer samples is not selected at ran-
dom. Specifically, in three out of the six cancer patients (Y,
B, and S), the early replicating allele was the large one,
showing the D-signal in 65% or more of SD cells for
CEN15. In the other three cases (J, A, and C), the early rep-
licating allele appeared to be the small one, showing the
D-signal in 60% or more of the SD-cells for CEN15 (Fig.
4d).
It is noteworthy that in the occasional SD-cell population
for CEN15 (low SD frequency) that appeared in the sam-
ples of non-cancer individuals, the selection for an early
or late replicating CEN15 allele appeared to occur at ran-
dom. This was evident from the equal frequencies (50%
each) of cells with an early replicating large allele and an
early replicating small allele observed in the SD-cell pop-
ulation for CEN15, in each of the six informative samples
of the non-cancer individuals (Fig. 4b). These small pop-
ulations of SD cells (usually found in synchronously rep-
licating regions) differ from the large SD-cell population
characterizing asynchronous replication and most likely
result from background noise.
Finally, we checked whether the non-random selection of
an early- or late- replicating CEN15 allele in the cancer
samples is a parent-of-origin-dependent process. Appar-
ently it is not. Proof comes from the lack of coordination
in the replication status between the CEN15-allele and the
SNRPN-allele assigned to the same homologue. The early
replicating CEN15 allele in cancer cases A and C resided
on the same homologous chromosome as the early repli-
cating SNRPN allele. On the other hand, in cancer cases Y
and J, the early replicating CEN15 and SNRPN alleles were
assigned to different homologues (bars Y, J, A, and C in
Fig. 4c and 4d). This indicates that the cancer-related asyn-
chronous replication in the CEN15 region, while clearly
not random, is guided by a mechanism other than a par-
ent-of-origin-dependent one.
Discussion
The asynchronous pattern of replication of the SNRPN-
imprinted locus, consisting of early replication of the
paternal allele (exemplified here in cells of the healthy
son (K2) of a non-cancer patient) is in accord with the
large amount of data documenting an allele-specific par-
ent-of-origin replication mode for this locus in normal
human cells [20-24]. The SNRPN pattern of replication
differs significantly from the normal synchronous pattern
observed for biallelically expressed genes
[19,25,26,35,39], shown here in cells of the non-cancer
patients by a non-transcribed locus – the chromosome-15
pericentromeric DNA array (CEN15).
However, in PHA-stimulated peripheral blood lym-
phocytes of the cancer patients, the SNRPN gene exhibited
a relaxation, almost a loss, leaving only remnants of its
characteristic asynchronous pattern of replication. This
confirmed our earlier finding that blood cells of patients
with urological cancers display relaxation in the asynchro-
nous pattern of allelic replication characterizing
imprinted loci [25,26]. It is noteworthy that loss of asyn-
chronous replication of SNRPN was used to confirm lack
of imprinting in cells of individuals carrying uniparental
disomy for the SNRPN locus [21,23,24,40]. In addition to
loss of the asynchronous replication of the imprinted
locus, the blood lymphocytes of the cancer patients stud-
ied here exhibited extreme changes in replication timing
of the CEN15 locus, which was asynchronous. These find-
ings confirm our previous findings of cancer-related, non-
locus specific replication timing alterations of loci (that
normally replicate synchronously) in blood lymphocytes
of patients with a solid tumor (see Introduction). Thus, an
aberrant epigenetic profile is seen in blood cells of cancer
patients, one marked by non-locus specific asynchronous
replication of normally biallelically expressed loci and
synchronous replication of imprinted genes.BMC Cancer 2008, 8:390 http://www.biomedcentral.com/1471-2407/8/390
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Yet, the aberrant epigenetic profile in blood cells of the
cancer patients was reverted to normal in the presence of
AZA, a classical methylation blocking agent, linking the
global cancer-related replication timing alterations to
methylation capacity (discussed later). These results are in
accord with findings that an AZA analog, 5-aza-2'-deoxy-
cytidine, which mimics AZA in its demethylation activi-
ties, restored the normal imprinting in cancer cells
exhibiting LOI [41,42]. Here, we show that AZA reinstated
the asynchronous replication of SNRPN in cells of the
cancer patients by re-establishing the advanced replica-
tion of the normally early replicating (paternal) allele.
This suggests that the cancer-related loss of asynchronous
replication of SNRPN  observed here resulted from
delayed replication (due to cancer-mediated hypermeth-
ylation) of the normally early replicating paternal allele,
rather than advanced replication of the normally late rep-
licating maternal allele. It cannot be ruled out, however,
that the loss of SNRPN asynchronous replication resulted
from advanced replication of the late replicating (mater-
nal) allele. In fact, classical reports of LOI documented
that cancer related relaxation of imprinting may arise
either from activation of the normally silent allele or from
inactivation of the normally expressed allele [36,43].
CEN15-replication behaviour, in normal situations as
well as in reaction to cancer status and to the methylation
blocking agent, completely mimics a biallelically
expressed locus. This is shown here by the similarity
between the CEN15 and the retinoblastoma gene RB1: the
first known tumor suppressor gene, also the first to show
an epigenetic inactivation – hypermethylation – rather
than a genetic inactivation in a tumor suppressor gene,
and to disclose that this inactivation was linked to an
allele-specific event [38]. It is therefore reasonable to
assume that CEN15  fully characterizes biallelically
expressed loci; and, assuming that SNRPN reliably repre-
sents an imprinted locus, it appears that LOI is only one
aspect of a much broader cancer-related epigenetic altera-
tion, namely, loss of the inherent coordination between
alleles. This alteration is neither locus- nor disease-spe-
cific, and is erased in the presence of AZA-like methyla-
tion-blocking agents. The alteration was evidenced here
by loss of replication timing properties of three unrelated
loci in blood cells of prostate cancer patients.
The FISH replication assay as used here (avoiding S-phase
cells labeling) is a simple and reliable method for replica-
tion timing analysis. First, we show here that in the nor-
mal samples, it repeats results obtained by others in
labeled S-phase cells [17,18,20-24]. Second, it is evident
that the considerably low frequency of SD cells for SNRPN
characterizing the cancer cases cannot be attributed to
shortening of the duration of the S-phase since at the same
time these same samples revealed a significant increase in
the frequency of SD cells for CEN15 and RB1. Similarly,
while an increase in the S-phase duration may explain the
increase in the frequency of SD cells for CEN15 and RB1,
it fails to explain the dramatic decrease in the frequency of
SD observed for the SNRPN locus. Furthermore, because
FISH uses single cells rather than bulks of DNA, it appears
to be especially sensitive for differentiating between the
synchronous and asynchronous modes of allelic replica-
tion. In addition, the assay estimates only stages prior to
or after termination of the whole replication process of
each counterpart of a tested locus, rather than pooled S-
phase cells, some of which are trapped in the course of the
replication process of the tested locus [15,17,18].
Using cell samples of cancer patients that are hetero-
zygous for a size polymorphism at the CEN15 region ena-
bled us to show that the selection of an allele for early or
late replicating in the cancer-related asynchronous repli-
cation was not random; in each sample, most of the
informative cells revealed one specific allele exhibiting
early replication, either the small or the large one. This
non-random choice was not dependent on the parental
origin of CEN15, because in some cases the early replicat-
ing CEN15 allele was assigned to the same chromosome
on which the early replicating SNRPN  locus resided
(paternal chromosome), and in others on the chromo-
some carrying the late replicating SNRPN locus (maternal
chromosome). This suggests that the selection of a CEN15
allele for allele-specific replication in the cells of cancer
patients is similar to the choice of an early (active) or late
(inactive) replicating chromosome in the process of X-
inactivation [44,45]; furthermore, it resembles the selec-
tion of the early (active) allele in the process of allelic
exclusion [11,15]. Neither mechanism is parent-of-origin-
dependent, but both (one made on the chromosome level
and the other on the allelic level) ensure that the selected
homolog (allele) for early (or late) replication passes the
information from one generation to the next in a cell lin-
eage. However, the mechanism that renders the two cop-
ies of a locus different from one another is unknown.
It was proposed that a normally existing variation in the
accumulation of long interspersed nuclear elements
(LINE)-1 facilitates differentiation between homologous
counterparts for X-inactivation [46], as well as for the
allele-specific expression of autosomal genes [47]. Since
considerably high densities of LINE-1 repeats also appear
in various autosomal regions not known to exhibit allelic
differences in gene expression, the role of LINE-1 repeats
in the mechanism initiating allelic functional asymmetry
seemed doubtful [47]. However, recent data showing that
monoallelically expressed genes are more widespread on
autosomes than expected [48] may strengthen the LINE
hypothesis, raising the possibility that the cancer status
takes advantage of such a variation. Furthermore, it seemsBMC Cancer 2008, 8:390 http://www.biomedcentral.com/1471-2407/8/390
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that those recently discovered autosomal monoallelically
expressed genes retain an inherent functional plasticity
with regard to monoallelical and biallelical expression
[2,48], which may facilitate the shifting from one mode of
expression to the other in response to malignancy.
Different nuclear positions of alleles in the interphase
nucleus at the S-phase were reported to accompany allelic
asymmetry [10,12,18]. Hence, one may speculate that the
epigenetic disequilibrium linked to the cancer phenotype
[36] alters the spatial DNA organization within the
nucleus, positioning each of the parental sets at a different
replication domain and thereby affecting the epigenetic
symmetry of various genes at once.
The mechanism involved in maintenance of allele-specific
replication, observed here in response to cancer, may
resemble that involved in maintaining the functional
asymmetry between the two homologous counterparts
resulting from both X-inactivation and allelic exclusion.
Both these processes are maintained by the methylation
capacity of the genome [11,49], similar to what we
observed in the cancer-related asynchronous replication.
However, the asynchronous replication acquired by the
cancer-status, probably later in life (shown here for
CEN15 and RB1 in cells of cancer patients), differs in the
response to AZA from that hatched normally into genes at
early developmental stages (exemplified here by SNRPN
in cells of non-cancer patients). We show here that the
former is reversed in the presence of AZA, and the latter is
unaffected. Our findings are in accord with reports claim-
ing that AZA-like drugs activate genes subjected to epige-
netic silencing, particularly if the silencing occurred due to
a pathological situation, making these drugs efficacious in
treating cancer [50-52]. Specifically, AZA and its analogs
are active only in S-phase cells, as they became incorpo-
rated (in place of cytosine) into replicating DNA. The
newly formed azacytosine-containing DNA blocks meth-
yltransferases activity [50]. As such, these drugs generates
heritably demethylated DNA, and, thus, activate silent
genes, shifts replication timing of various DNA sequences
to early replication S-phase domains [53].
According to our results, each of the cancer patients had
an allele-specific replication mode for loci that normally
replicate in the classical biallelic-mode. Each of the non-
cancer patients showed the expected synchronous pat-
terns of replication for each of these loci. Taken together,
these results suggest that the aberrant replication mode is
a response to the disease and not an inborn- or age-
acquired cancer-predisposing epigenetic marker. This
holds true also for the aberrant replication shown for the
imprinted locus. This concept is strengthened by the fact
that the non-cancer patients tested here were at an
advanced age and therefore at increased risk for develop-
ing cancer compared to the normal population. Hence,
the allele-specific labelling, in contrast to X-inactivation
and allelic exclusion, most probably occurs during the
lifespan of an individual rather than at the prenatal early
developmental stages. This accords with the idea that epi-
genetic alterations associated with modifications in meth-
ylation capacity may take place later in life as well [50,54].
However, it should be emphasized that the cancer-based
aberrant patterns of replication are not age dependent, as
they characterize young cancer patients as well as elderly
ones [35].
Finally, a cancer-related, non-disease specific, aberration
observed for a large number of loci in a single cell sample,
achieved by low invasive means, offers a way to identify
potential epigenetic biomarkers for cancer detection and
disease follow up. Besides, an aberration that can be
reversed to normal by an epigenetic drug applied in vitro
may provide a candidate marker for cancer drug evalua-
tion.
Conclusion
The cancer-related, non-locus specific, allelic replication
timing aberration, observed in peripheral blood cells, is
linked to aberrant methylation and may be reversed to
normal by an epigenetic drug applied in vitro. It is analo-
gous, although broader in manifestation, to loss of
imprinting, a phenomenon widely associated with malig-
nancy. The choice of an allele for early or late replication
in the cancer-related asynchronous replication is not ran-
dom but independent of the parental origin.
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